Xenetic Biosciences Inc (XBIO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.73 (+10.98%), Market cap $0.01B, 52-week low–high $2.02 ~ $10.36.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various res
Financial statements, price targets, institutional (13F) holdings and related news for Xenetic Biosciences Inc are updated in real time on BlackAll Trade.
Xenetic Biosciences Inc trades at $2.73 (+10.98%). Real-time quotes and charts are available on BlackAll Trade.
Xenetic Biosciences Inc has a market cap of about $0.01B.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which ar